VoxNeuro announces collaboration with the Canadian Armed Forces and the launch of a clinical study measuring the impact of training-related subconcussive exposure

TORONTO–(BUSINESS WIRE)–VoxNeuro Inc. (“VoxNeuro“or the”Company”), a commercial-stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, announced a new partnership with the Canadian Armed Forces (“CIF”).

VoxNeuro and CAF have partnered to study the cognitive effects following intense military training programs designed to reflect a combat environment and exposure to blasts. Despite the high prevalence of cognitive problems among veterans and active military personnel, there is relatively little understanding regarding these cognitive effects and reliable monitoring.

The study will assess the effects of repetitive subconcussive exposure (RSCE) on cognitive functioning and brain electrophysiology in CAF personnel undergoing cognitive testing in tandem with EEG recordings before and after military training. The study aims to understand the relationship between RSCE and behavioral symptoms, vestibular dysfunction, neurophysiology and cognition to aid in early detection, prevention, treatment and prognosis.

The study will be led by Dr. Kyle Ruiter, PhD, Vice President of Clinical and Scientific Affairs of VoxNeuro, with support from Dr. John Connolly, PhD, Chief Scientific Officer of VoxNeuro. “We are excited to have the opportunity to conduct research with the Canadian Armed Forces that will help us better understand the cognitive performance of elite military personnel during high-intensity combat situations,” said Dr. Ruiter. “We hope this research will be an important step in improving the brain health and safety of the Canadian Armed Forces and other service members.

VoxNeuro and CAF want this study to lay the groundwork for future collaborative research for years to come. The goal is to understand how to best improve the diagnosis of brain injury in active military personnel who are exposed to RSCE and use this information to refine VoxNeuro’s existing test platform in the market. The Company intends to use this work to support new regulatory filings with Health Canada and the FDA.

About VoxNeuro – Give the brain a voice

VoxNeuro pushes the boundaries of brain health and offers healthcare providers breakthrough SaMD technology that uses validated brain biomarkers. The company’s EEG-based reports provide a comprehensive understanding of how a brain works through the objective measurement of a patient’s attention and concentration, information processing and working memory . VoxNeuro complements existing clinical workflow to provide clinicians and patients with a more complete picture of brain health and to inform clinical decision making.

Visit voxneuro.com to learn more.

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements under Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will happen”. These forward-looking statements are subject to a number of risks and uncertainties. Actual results may differ materially from the results contemplated by the forward-looking statements. Accordingly, actual events may differ materially from those projected in the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements except as required by applicable securities laws.